41 results
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
11 Jun 24
Regulation FD Disclosure
9:15pm
in continued, substantial improvements in bone mineral density (BMD) with a mean increase from baseline of 22% (p<0.0001) and a substantial mean … spine bone mineral density (BMD) at month 12 without evidence of plateau.
The large reduction in annualized radiologically confirmed fracture rate
8-K
MREO
Mereo Biopharma Group Plc
11 Jun 24
Regulation FD Disclosure
9:15pm
-up. Treatment with setrusumab also resulted in ongoing and meaningful improvements in lumbar spine bone mineral density (BMD) at month 12 without
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
. The study also evaluated numerous other endpoints, including bone mineral density (“BMD”) and annualized fracture rates, PK and safety. Across all
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
4:08pm
. This reduction was associated with improvements in bone mineral density (BMD). Setrusumab was well-tolerated with no serious adverse events or drug-related
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
8 Jan 24
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
7:08am
with setrusumab reduced the annualized fracture rate by 67%. This reduction was associated with continuing large and meaningful improvements in bone mineral
6-K
EX-99.1
zx9yqoo
23 Oct 23
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
4:08pm
6-K
35qh vqwjo5zedpos
17 Oct 23
Current report (foreign)
7:01am
6-K
EX-99.1
4qmwxhavrq 68nyozzsf
17 Oct 23
Current report (foreign)
7:01am
6-K
EX-99.3
16l 3inh66
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.2
1cwfs
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.1
7okq22v54bw k70i
6 Jul 23
Ultragenyx Announces First Patients Dosed in Phase 3 Program
8:05am
6-K
0fgt9rop50erzuqo 85
7 Jun 23
Current report (foreign)
8:41am
6-K
EX-99.1
ghg942deppp
5 Jun 23
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit
4:37pm
6-K
EX-99.2
a9uh0 km7b
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.2
d4mydlnvm qswb
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.2
3rufjxr1yct4s yc92
2 Nov 21
Current report (foreign)
4:16pm
6-K
axdlkghtxhm5xm
1 Oct 21
Current report (foreign)
4:43pm
6-K
EX-99.1
7gjcxrp
1 Oct 21
Current report (foreign)
4:43pm
F-3/A
scalhr3rto1vxxuab
27 Sep 21
Shelf registration (foreign) (amended)
4:18pm